Together, these previous findings led to the notion that inhibition of IRE1α might provide a new therapeutic strategy for controlling the excessive inflammation of CF airways by targeting the activity of this ER stress protein in multiple cell types. This evidence concerns the gene ERN1 and cystic fibrosis.